J&J pauses US rollout of Varipulse heart device

The temporary pause will allow the company to investigate four neurovascular events seen in an external evaluation study.
The temporary pause follows reports of four cases of neurovascular events in the US external evaluation study.
Johnson & Johnson (JNJ) stock fell after pausing use of its Varipulse Pulsed Field Ablation Platform. Read more here.
Johnson & Johnson stock skidded Wednesday after the company temporarily paused sales of its pulsed field ablation system.
The report, spearheaded by analyst Larry Biegelsen, pointed to conversations with physicians and industry contacts indicating that Johnson & Johnson has possibly paused Varipulse procedures because of ...